|
1. Biologie
|
|
|
|
3. Prévention
|
|
|
|
|
3.1 Tabac
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
It’s The Antigens, Stupid [LifeSciVC]
|
|
|
|
|
|
We
may indeed find therapeutic windows for some of these drugs/combos for
some patients, but in general, we still seem to be activating large
portions of the immune system with dubious benefit and occasionally
quite meaningful harm.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
How Big Can Merck's Keytruda Be In Lung Cancer? [Forbes]
|
|
|
|
|
|
There
are two points there. One is that there might be a different way to
divide up cancer patients based on PDL1 status, which might increase the
size of Merck’s pie. The second is that the label will include
information about treating patients who didn’t have high PDL1 status,
and that doctors (or perhaps insurers?) might decide to use Keytruda
instead of Opdivo anyway.
|
|
|
|
|
|
|
|
Major Drug Companies Report Solid Results [Wall Street Journal]
|
|
|
|
|
|
Merck
reported $83 million in first-quarter sales for Keytruda, while
Bristol-Myers reported $40 million in sales for Opdivo, which hit the
U.S. market a few months after Keytruda last year. Sales of Ibrance,
which works by blocking molecules that help tumor-cells grow, were $38
million.
|
|
|
|
|
|
|
5.9.4 AACR - poumon
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
Lottery of cancer survival revealed [The Telegraph]
|
|
|
|
|
|
The
figures show that for women with lung cancer 5-year survival was 7.2
per cent in Surrey and Sussex area, compared with 12.1 per cent in East
Anglia. For men with prostate cancer 5-year survival was 70.9 per cent
in Derbyshire and Nottinghamshire, compared with 86.3 per cent in the
Birmingham and the Black Country area.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|